Plexure (ASX: PX1) gets another endorsement from Maccas

Nick Sundich Nick Sundich, August 1, 2022

Plexure (ASX: PX1) has been through a difficult time since listing, but got some respite this morning. The New Zealand-founded mobile engagement platform listed on the ASX in late 2020, having already listed on the NZX.  

When it listed, one of its key selling points to investors was that McDonalds backed it as a client and an investor – it owns just over 4% of the firm. This morning, the fast-food giant gave Plexure another endorsement.   

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

Who is Plexure? 

Plexure is a company that helps consumer brands deliver one on one offers through their mobile devices. These individual offers are designed to drive traffic to physical stores. In the 12 months to 31 March 2022, it achieved NZ$32.6m in revenue, but an EBITDA loss of $15.6m.  

Shares have suffered as investors turned away from non-profitable companies. Although McDonalds has backed the company, PX1 struggled to broaden its customer base. A merger with Australian group Task did little to help broaden its appeal, even though it won some notable deals – including with Accor Stadium in Sydney. 

 

plexure

Plexure (ASX:PX1) share price chart (Graph: TradingView)

 

Another deal from McDonalds and solid FY23 guidance 

But this morning, shares rose over 80% off the back of two pieces of goods news. First, McDonalds signed another 5-year contract with the company. And secondly, it gave guidance for FY23 which indicated profitability. For the year ending 31 March 2023, it is expecting NZ$56m in revenue, up over 70% from FY22, and $3.7m in positive EBITDA. 

Plexure is one of several companies that have been through one-day jumps after announcing that profitability was expected in the forthcoming financial year. But for companies such as Plexure, with a history of under-delivering, we would exercise caution until it actually achieves these results (at least on a half-yearly basis).  

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

Kamala Harris stocks

Kamala Harris stocks: If Joe Biden’s VP wins the White House in 2024, which stocks will win?

With the US Presidential election now certain to be a Kamala Harris v Donald Trump showdown, we’ve looked at so-called…

South32

South32 (ASX:S32): Is it the dark horse amongst ASX 200 miners or have cyclones and commodity prices hit it too hard?

South32 (ASX:S32) began life as a spinoff from BHP back in 2015, capitalised at $9bn. In mid-2024, it is capped…

drug reimbursement

Here’s why drug reimbursement is so important for ASX healthcare stocks

Let’s take a look at the concept of drug reimbursement, something that is crucial for ASX healthcare stocks looking to…